Table 1.

Baseline characteristics of Chronic Renal Insufficiency Cohort Study participants by anemia status

CharacteristicNo Anemia (n=2060)Anemia (n=1859)
Age, yr57.6 (11.1)a58.8 (10.9)
Women901 (44%)869 (47%)
Race/ethnicity
 Non-Hispanic white1067 (52%)a564 (30%)
 Non-Hispanic black713 (35%)925 (50%)
 Hispanic183 (9%)313 (17%)
 Other97 (5%)57 (3%)
Income ≤$20,000500 (24%)a729 (39%)
Education less than high school285 (14%)a536 (29%)
Health insurance1736 (93%)1491 (91%)
Nephrology care1289 (63%)a1296 (70%)
Hypertension1675 (81%)a1698 (91%)
Diabetes700 (34%)a1198 (64%)
Cardiovascular disease591 (29%)a717 (39%)
Current smoker284 (14%)b229 (12%)
Medications
 ACE inhibitor or ARB1304 (64%)a1372 (74%)
β-Blocker936 (46%)a984 (53%)
 Aspirin or antiplatelet866 (42%)a928 (50%)
 Statin1013 (50%)a1128 (61%)
 Erythropoiesis-stimulating agent38 (2%)a115 (6%)
 Iron87 (4%)a257 (14%)
Systolic BP, mm Hg124.7 (20.9)a132.7 (22.8)
Body mass index (kg/m2)31.7 (7.1)a32.54 (8.49)
Transferrin saturation, %25a22
Ferritin, ng/ml, median (IQR)156.8 (86.0–276.5)a159.4 (80.6–299.3)
Serum albumin4.1 (0.4)a3.8 (0.5)
Hemoglobin A1c6.4 (1.4)a7.0 (1.7)
LDL cholesterol, mg/dl106.8 (35.0)a98.3 (35.8)
Calcium, mg/dl9.3 (0.5)a9.1 (0.5)
Phosphate, mg/dl3.6 (0.6)a3.9 (0.7)
Total parathyroid hormone, pg/ml46.3 (32.0–73.0)a65.6 (39.8–114.0)
C-reactive protein, mg/L2.4 (1.1–5.7)a2.8 (1.1–7.4)
eGFR, ml/min per 1.73 m250.3 (17.4)a38.9 (14.0)
Urine protein, g/24 h, median (IQR)0.13 (0.07–0.61)a0.3 (0.08–1.40)
Hemoglobin, g/dl13.9 (1.2)a11.2 (1.1)
Mean cell volume, fl89.1 (5.0)a87.3 (6.6)
  • Mean (SD or %) or median (interquartile ranges) are provided for normally and non-normally distributed variables, respectively. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; IQR, interquartile range.

  • a P<0.01.

  • b P<0.05.